Dr. Garfield is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
7600 Landmark Way, unit 901
Centennial, CO 80111Phone+1 303-748-8617- Is this information wrong?
Summary
- Dr. David Garfield is a retired medical oncologist now living in the Denver and Scottsdale areas. He received his medical degree from University of Illinois College of Medicine and was in practice almost 50 years. He specialized in breast cancer and thoracic cancer. He practiced medical oncology in Shanghai from 2010 to 2013 and still consults there.
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1969 - 1971
- University of MinnesotaResidency, Internal Medicine, 1967 - 1969
- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1964 - 1965
- University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1963 - 1964
- University of Illinois College of MedicineClass of 1963
- Northwestern UniversityAccelerated Pre-Med Program, 1956 - 1959
Certifications & Licensure
- CO State Medical License Active through 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top 75 (5%) Reviewers for Chest 2009
- Service Award U.S. Oncology, 2001
- Service Award American Cancer Society, Denver Unit, 2000
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsDistribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.Wei Wang, Xiaosong Chen, Lin Lin, Xiaochun Fei, David H. Garfield, Jin Hong, Weiqi Gao, Siji Zhu, Jiayi Wu, Ou Huang, Jianrong He, Yafen Li, Li Zhu, Weiguo Chen, Kunwe...> ;Journal of Cancer. 2018 Aug 6
- 6 citationsCan Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node...Yue Liang, Xiaosong Chen, Weiwei Zhan, David H. Garfield, Jiayi Wu, Ou Huang, Yafen Li, Li Zhu, Weiguo Chen, Kunwei Shen> ;Annals of Surgical Oncology. 2017 Feb 6
- Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-...Wang SF, Wang Q, Jiao LJ, Huang YL, Garfield D, Zhang J, Xu L> ;Curr Oncol. 2016-06-01
- Join now to see all
Journal Articles
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerLi B, Ren S, Li X, Wang Y, Garfield D, et al, Lung Cancer, 11/13/2013
- Prevalence of lymph node metastases in superficial esophageal squamous cell carcinomaLi B, Chen H, Xiang J, Zhang Y, Kong Y, Garfield DH, et al, J Thorac Cardiovasc Surg, 8/26/2013
- Practicing Western Oncology in Shanghai, China: One Group's ExperienceGarfield DH, Brenner HJ, Lu L, J Oncol Pract, 7/1/2013
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Effects of gefitinib (G) on bone metastases (BMs) in non-small cell lung cancer (NSCLC) patients (pts).Garfield DH, Zampa G, Cadranel J, et al, American Society of Clinical Oncology, 1/1/2006
- "Phase 2 Trial of Single-Agent, Weekly Docetaxel as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer."Canfield V, Garfield D, et al, American Society of Clinical Oncology, 1/1/2002
- "Phase 2 Study of Sequential Chemotherapy Followed by Oral Maintenance Therapy with Orzel (UFT + Leukovorum) in Patients with Stage 3B and 4 Non-Small Cell Lung Cancer."Marsland, T, Garfield, D, et al, American Society of Clinical Oncology, 1/1/2002
- Join now to see all
Lectures
- "Phase II comparative study of two dose schedules of gemcitabine (Gem) as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC)."Paris, France - 2/3/1998
Other
- Monograph: "Molecular targeted therapy in oncology for the 21st century: bench to bedside."Iwata KK, Haley JD, Garfield DH
1/1/2006 - Bronchioloalveolar Carcinoma (BAC): New insights in epidemiology, pathology, and novel strategies.West H(J), Garfield D, Lung Cancer, Principles and Practice, publisher: Lippincott Williams @ Wilkins, vol. 3
1/1/2004
Authored Content
- Distribution and Clinical Utility of the 21-Gene Recurrence Score in Pure Mucinous Breast Cancer Patients: A Case-Control StudyAugust 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: